Evidence map›Paper›PMID 38887238›Full record

SynthesisFrontiers in oncology2024

A 23-year bibliometric analysis of the development of global research on hereditary renal carcinoma.

Xiaopeng Lan, Mei Feng, Ji Lv, Luchen Zhang, Pengcheng Hu, Yizhen Wang, Yanhui Zhang, Shen Wang, Chunzhao Liu, Chunlei Liu

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiaopeng LanDepartment of Urology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, China.
Mei FengDepartment of Urology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, China.
Ji LvDepartment of Urology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, China.
Luchen ZhangDepartment of Urology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, China.
Pengcheng HuDepartment of Urology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, China.
Yizhen WangDepartment of Urology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, China.
Yanhui ZhangDepartment of Urology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, China.
Shen WangDepartment of Urology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, China.
Chunzhao LiuInstitute of Biochemical Engineering, College of Materials Science and Engineering Qingdao University, Qingdao, China.
Chunlei LiuDepartment of Urology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Medical research continues to be extensively devoted to investigating the pathogenesis and treatment approaches of hereditary renal cancer. By aspect including researchers, institutions, countries, journals, and keywords, we conduct a bibliometric analysis of the literature pertaining to hereditary renal cancer over the last 23 years. Methods: From the Web of Science Core Collection, we conducted a search for publications published between January 1, 2000 and November 28, 2023. Reviews and original articles were included. Results: A cumulative count of 2,194 publications met the specified criteria for inclusion. The studies of the included articles involved a collective of 2,402 institutions representing 80 countries. Notably, the United States exhibited the highest number of published documents, constituting approximately 45.49% of the total. The preeminent institution in this discipline is the National Cancer Institute (NCI), which maintains a publication volume of 8.98%. In addition to being the most prolific author (125 publications), Linehan WM's works received the highest number of citations (11,985). In a comprehensive count, 803 journals have published related articles. In the top 10 most recent occurrences were the terms "hereditary leiomyomatosis" and "fumarate hydratase." Conclusion: This is the first bibliometric analysis of the literature on hereditary renal cancer. This article offers a thorough examination of the present status of investigations concerning hereditary renal cancer during the previous 23 years.

Indexed as

bibliometric analysisBirt Hogg Dube syndromehereditary leiomyomatosis and renal cell carcinomahereditary papillary renal cell carcinomahereditary renal cancerHippel-Lindau diseasetuberous sclerosis complex

Identifiers

PMID38887238
PMCPMC11180816

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.